286 related articles for article (PubMed ID: 31791846)
1. Cervical Cancer Screening: Past, Present, and Future.
Bedell SL; Goldstein LS; Goldstein AR; Goldstein AT
Sex Med Rev; 2020 Jan; 8(1):28-37. PubMed ID: 31791846
[TBL] [Abstract][Full Text] [Related]
2. The degree of agreement between HPV testing, pap smear and colposcopy in cervical dysplasia diagnosis.
Melinte-Popescu A; Costăchescu G
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):536-9. PubMed ID: 23077949
[TBL] [Abstract][Full Text] [Related]
3. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
5. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
[TBL] [Abstract][Full Text] [Related]
7. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
10. Impact of human papillomavirus (HPV) self-collection on subsequent cervical cancer screening completion among under-screened US women: MyBodyMyTest-3 protocol for a randomized controlled trial.
Spees LP; Des Marais AC; Wheeler SB; Hudgens MG; Doughty S; Brewer NT; Smith JS
Trials; 2019 Dec; 20(1):788. PubMed ID: 31881928
[TBL] [Abstract][Full Text] [Related]
11. Management of cervical precancers: a global perspective.
Echelman D; Feldman S
Hematol Oncol Clin North Am; 2012 Feb; 26(1):31-44. PubMed ID: 22244660
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador.
Campos NG; Alfaro K; Maza M; Sy S; Melendez M; Masch R; Soler M; Conzuelo-Rodriguez G; Gage JC; Alonzo TA; Castle PE; Felix JC; Cremer M; Kim JJ
Prev Med; 2020 Feb; 131():105931. PubMed ID: 31765712
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination.
Zhu Y; Wang Y; Hirschhorn J; Welsh KJ; Zhao Z; Davis MR; Feldman S
Adv Clin Chem; 2017; 81():135-192. PubMed ID: 28629588
[TBL] [Abstract][Full Text] [Related]
14. Screening for cervical cancer: new alternatives and research.
Lörincz AT
Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa.
Tsu VD; Njama-Meya D; Lim J; Murray M; de Sanjose S
Prev Med; 2018 Sep; 114():205-208. PubMed ID: 30031013
[TBL] [Abstract][Full Text] [Related]
16. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
[TBL] [Abstract][Full Text] [Related]
17. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
[TBL] [Abstract][Full Text] [Related]
18. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ
Int J Cancer; 2015 Aug; 137(4):893-902. PubMed ID: 25639903
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
